SearchDictionaryMobileLogin

Juvenile Rheumatoid Arthritis (Juvenile Idiopathic Arthritis)

Subscribe to Selected New Research on Juvenile Rheumatoid Arthritis
1958  relevant articles (142 outcomes, 236 trials/studies) found for this Disease

Description: Rheumatoid arthritis of children occurring in three major subtypes defined by the symptoms present during the first six months following onset: systemic-onset (Still's Disease, Juvenile-Onset), polyarticular-onset, and pauciarticular-onset. Adult-onset cases of Still's disease (STILL'S DISEASE, ADULT-ONSET) are also known. Only one subtype of juvenile rheumatoid arthritis (polyarticular-onset, rheumatoid factor-positive) clinically resembles adult rheumatoid arthritis and is considered its childhood equivalent.

Also Known As:
Juvenile Idiopathic Arthritis; Juvenile Chronic Arthritis; Arthritis, Juvenile Rheumatoid; Juvenile-Onset Still Disease; Juvenile-Onset Stills Disease; Still Disease, Juvenile-Onset; Arthritides, Juvenile Idiopathic; Chronic Arthritis, Juvenile; Idiopathic Arthritides, Juvenile; Idiopathic Arthritis, Juvenile; Juvenile Idiopathic Arthritides; Juvenile Onset Still Disease; Juvenile Onset Stills Disease; Juvenile-Onset Still's Disease; Rheumatoid Arthritis, Juvenile; Still Disease, Juvenile Onset; Still's Disease, Juvenile Onset; Stills Disease, Juvenile-Onset; Arthritis, Juvenile Chronic; Arthritis, Juvenile Idiopathic; Still's Disease, Juvenile-Onset

Relationship Network

Disease Context: Research Results

-
Musculoskeletal Diseases: 87
-
Rheumatic Diseases: 5000
-
Rheumatoid Arthritis: 28802
*
Juvenile Rheumatoid Arthritis: 1958
-
Joint Diseases: 1574
-
Arthritis: 15067
-
Rheumatoid Arthritis: 28802
*
Juvenile Rheumatoid Arthritis: 1958
-
Skin and Connective Tissue Diseases
-
Connective Tissue Diseases: 1692
-
Rheumatic Diseases: 5000
-
Rheumatoid Arthritis: 28802
*
Juvenile Rheumatoid Arthritis: 1958
-
Immune System Diseases: 1319
-
Autoimmune Diseases: 12462
-
Rheumatoid Arthritis: 28802
*
Juvenile Rheumatoid Arthritis: 1958

Related Diseases

1. Rheumatoid Arthritis
2. Arthritis (Polyarthritis)
3. Uveitis
4. Psoriatic Arthritis
5. Pain (Aches)

Experts

1. Martini, A: 16 articles (07/2008 - 08/2000)
2. Kuis, W: 13 articles (09/2008 - 03/2000)
3. Martini, Alberto: 11 articles (08/2008 - 10/2002)
4. Ravelli, A: 10 articles (07/2008 - 08/2000)
5. Takei, Syuji: 10 articles (01/2008 - 04/2002)
6. Lovell, Daniel J: 9 articles (08/2008 - 01/2003)
7. Gerloni, V: 9 articles (07/2008 - 10/2003)
8. Prieur, Anne-Marie: 9 articles (09/2007 - 06/2002)
9. Wulffraat, N M: 9 articles (07/2007 - 03/2000)
10. Giannini, Edward H: 8 articles (08/2008 - 07/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Juvenile Rheumatoid Arthritis:
1. TNFR-Fc fusion protein (etanercept)FDA Link
2. Methotrexate (Mexate)FDA LinkGeneric
04/01/2009 - "An improved high-performance liquid chromatography method for quantification of methotrexate polyglutamates in red blood cells of children with juvenile idiopathic arthritis."
07/01/2000 - "The results demonstrated the following: (1) radiographic evidence of condylar degeneration was apparent in 63% of all patients with juvenile rheumatoid arthritis with pauciarticular patients showing less temporomandibular involvement than polyarticular patients; (2) polyarticular juvenile rheumatoid arthritis patients receiving methotrexate showed less severe temporomandibular joint involvement than the polyarticular patients not receiving methotrexate; (3) the craniofacial structure was affected to a greater extent in the polyarticular form of the disease; (4) the craniomandibular index scores were significantly greater in the polyarticular group; (5) vertical height asymmetry and chin deviation were noted in more than 50% of the patients; and (6) there was a correlation between the severity of condylar lesions and cephalometric findings (ie, mandibular retroposition, posterior rotation, smaller ramus and mandibular dimensions) and the onset and duration of the disease. "
07/01/2004 - "OBJECTIVE: To compare the safety and efficacy of parenteral methotrexate (MTX) at an intermediate dosage (15 mg/m(2)/week) versus a higher dosage (30 mg/m(2)/week) in patients with polyarticular-course juvenile idiopathic arthritis (JIA) who failed to improve while receiving standard dosages of MTX (8-12.5 mg/m(2)/week). "
07/01/2000 - "In conclusion, under the conditions of this study, methotrexate therapy was effective in minimizing temporomandibular joint destruction and craniofacial dysmorphology in juvenile rheumatoid arthritis patients with the polyarticular form of the disease."
04/16/1992 - "Methotrexate may also be effective in children with resistant juvenile rheumatoid arthritis, but the supporting data are from uncontrolled trials. "
Order ALL the reference details at left...
3. Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
4. Interleukin-6 (Interleukin 6)IBA
5. tocilizumabIBA
6. Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link
7. infliximab (Remicade)FDA Link
8. Auranofin (Ridaura)FDA Link
9. Penicillamine (Cuprimine)FDA Link
10. Aspirin (Acetylsalicylic Acid)FDA LinkGeneric

Therapies and Procedures

1. Arthroplasty
2. Injections
3. Exercise Therapy (Therapy, Exercise)
4. Immunotherapy
5. Drug Therapy (Chemotherapy)

Best Treatments:
Research Summary Report
on Juvenile Rheumatoid Arthritis

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.
  • Free Updates for 1 Year
  • All 142 Outcomes
  • Top 200 Key Drugs and Biologics
  • Top 50 Key Therapies and Procedures
  • Detailed History Charts
  • Full Research Reference Details
  • Sample PDF Report on Psoriasis >>
Price:$24.00 & Delivery via PDF download
updates for 1 year
Research Interface

 

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.
  • Unlimited Disease, Drug and Therapy Search
  • 2 clicks from Disease to Drug to Evidence
  • Trial References
  • All the Positive Outcomes
  • Detailed Relationship Timeline Charts
  • Full Article Reference Details
  • Includes Mobile Interface Subscription
  • One-click to FDA Products/Patents
  • Request Institution License Details >>
Price:$490.00 access via web interface
1 year subscription
Proceed to Checkout >>
Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.
  • Access from any web enabled PDA or Phone
  • Trial references
  • All the Positive Outcomes
  • Drug and Therapy searches
  • Full Article Reference Details
  • Try Mobile Interface >>
Price:$45.00 access via "curehunter.com/m"
1 year subscription
Proceed to Checkout >>